Market Cap$18.12B
P/E25.58x
PEG Ratio0.60
Div yield1.04%
Beta0.49
ZBH Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-11.50%
Price vs S&P 500 (4W)2.02%
PEG Ratio0.60
VGM Score62.27
P/E Ratio (Annual)25.58x
Indicated Dividend Yield (Annual)1.04%
ZBH Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.01 | $2.07 | +2.99%(+$0.06) | |
| Q1 2026 | $1.86 | $2.09 | +12.21%(+$0.23) | |
| Q4 2025 | $2.40 | $2.42 | +0.93%(+$0.02) | |
| Q3 2025 | $1.87 | $1.90 | +1.83%(+$0.03) | |
| Q2 2025 | $1.98 | $2.07 | +4.75%(+$0.09) |
ZBH Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.41
3.41
3.42
3.42
Industry Peers — Orthopedic & Prosthetic Devices(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
ZBHZimmer Biomet Holdings, Inc. | B | C | B | 2.1x | 3.2% | 69.9% | 14.2% | $94.98 |
| ISRGIntuitive Surgical Inc. | D | B | B | 13.7x | 18.2% | 66.7% | 31.3% | $426.70 |
| EWEdwards Lifesciences Corp | D | C | B | 7.7x | 6.7% | 77.8% | 18.2% | $86.60 |
| STESTERIS plc | C | C | B | 3.6x | 13.8% | 44.4% | 18.9% | $222.66 |
| SNNSmith & Nephew plc | B | C | C | 1.9x | 6.2% | 68.2% | 12.9% | $29.06 |
| ALGNAlign Technology Inc | B | D | C | 2.5x | 10.3% | 69.0% | 13.2% | $147.31 |
| MSAMine Safety Incorporated | C | C | B | 3.5x | 6.8% | 47.6% | 21.2% | $179.05 |
| ESTAEstablishment Labs Holdings Inc. | F | A | C | 7.2x | 20.0% | 70.5% | -7.6% | $59.18 |
| ENOVEnovis Corporation | B | D | C | 0.5x | -6.0% | 61.4% | -45.1% | $19.59 |
| CDRECadre Holdings, Inc. | B | C | C | 1.6x | 8.6% | 41.8% | 10.1% | $26.38 |
| AVRAnteris Technologies Global Corp. Common Stock | D | C | C | 263.0x | — | 75.0% | -4738.4% | $6.05 |
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet is a leading designer and manufacturer of orthopedic reconstructive implants and surgical equipment, with dominant market positions in the United States, Europe, and Japan. The company derives approximately two-thirds of revenue from large joint reconstructions, with the remainder from trauma, sports medicine, and extremities products. In 2022, Zimmer spun out its dental and spine businesses to focus on orthopedic reconstruction.